Table 2.

Significance comparison of pathological change in liver and serum HBV DNA clearance rate between Non-MASLD and MASLD group.

	Non-MASLD 226	MASLD 177	P-value
	Liver Pathological Feature
Necroinfammation, n (%)			0.015
non-significant	109 (48.23%)	64 (36.16%)
significant	117 (51.77%)	113 (63.84%)
Fibrosis, n (%)
non-significant	164 (72.57%)	108 (61.02%)	0.014
significant	62 (27.43%)	69 (38.98%)
Damage†, n (%)			0.050
non-significant	93 (43.15%)	56 (31.64%)
significant	133 (58.85%)	121 (68.36%)
	Serum HBV DNA Clearance
HBV DNA negative, n (%)			0.002
Yes	135 (59.73%)	132 (74.58%)
No	91 (40.27%)	45 (25.42%)

MASLD, metabolic dysfunction-associated steatotic liver disease.

^† Liver damage (Necroinfammation and/or Fibrosis).